BURLINGTON, Mass., Nov. 12, 2014 /PRNewswire/ -- Decision Resources Group finds that the European pain management device market generates a majority of revenue from select products, such as spinal cord stimulation (SCS) and radiofrequency (RF) ablation devices. This results in key players like Medtronic and St. Jude Medical capturing significant share. Increasing recognition of the value of pain management devices over pharmaceuticals will, however, drive moderate market growth, leading to increased competition as manufacturers shift focus to the device market.

Other key findings from Decision Resources Group's coverage of the European pain management device market:

  • SCS product mix: Similar to the U.S. market, the majority of revenues in Europe were generated by SCS devices. However, the European and U.S. market differ significantly in the types of devices used; while U.S. physicians prefer rechargeable devices, the European market is still strongly dominated by less expensive primary cell devices.
  • Device markets in Italy and Spain: The lingering impact of the Eurozone debt crisis has resulted in the Italian and Spanish device markets being highly cost-conscious, with physicians opting for lower-priced products to manage pain, such as disposable ambulatory infusion pumps.
  • Cooled RF ablation: Cooled RF ablation remains a niche segment within the European pain management device market. While scientific literature strongly backs this procedure, European physicians are unconvinced that it offers much benefit over standard RF ablation.

Comments from Decision Resources Group Principal Analyst Mickel Phung:

  • "The different preferences of European physicians have resulted in a much different competitive landscape compared to the United States. For example, Boston Scientific, which only offers a rechargeable SCS device, and Kimberly-Clark, which offers a cooled RF ablation system, have much lower shares in Europe."
  • "St. Jude Medical has recently bolstered its share with the acquisition of NeuroTherm, an RF ablation device company. NeuroTherm had gained a leading position in the European RF ablation device market through its affordable pricing strategy, which is highly appealing to cost-conscious European facilities. With this acquisition, St. Jude Medical now has a diverse portfolio of pain management devices aimed at the treatment of back pain, the largest chronic pain patient population in Europe."

Additional Resources:

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

The Ulcerative Colitis Market Will Grow Over the Next Decade, Reaching $4.2 Billion in 2023

View Now